Patents Examined by Sean Aeder
  • Compositions and methods comprising KLK3 of FOLH1 antigen
    Patent number: 9012141
    Abstract: The present invention provides KLK3 peptides, FOLH1 peptides, recombinant polypeptides comprising same, recombinant nucleotide molecules encoding same, recombinant Listeria strains comprising same, and immunogenic and therapeutic methods utilizing same.
    Type: Grant
    Filed: May 10, 2007
    Date of Patent: April 21, 2015
    Assignees: Advaxis, Inc., The Trustees of the University of Pennsylvania
    Inventors: Yvonne Paterson, John Rothman, Vafa Shahabi
  • Cysteine engineered antibodies and conjugates
    Patent number: 9000130
    Abstract: Cysteine engineered antibodies comprising a free cysteine amino acid in the heavy chain or light chain are prepared by mutagenizing a nucleic acid sequence of a parent antibody and replacing one or more amino acid residues by cysteine to encode the cysteine engineered antibody; expressing the cysteine engineered antibody; and isolating the cysteine engineered antibody. Certain highly reactive cysteine engineered antibodies were identified by the PHESELECTOR assay. Isolated cysteine engineered antibodies may be covalently attached to a capture label, a detection label, a drug moiety, or a solid support.
    Type: Grant
    Filed: June 7, 2011
    Date of Patent: April 7, 2015
    Assignee: Genentech, Inc.
    Inventors: Sunil Bhakta, Jagath R. Junutula
  • Immunogenic control of tumours and tumour cells
    Patent number: 8999346
    Abstract: The present invention relates to the use of immunogenic peptides comprising a T-cell epitope derived from a tumour-associated antigen and a redox motif such as C-(X)2-[CST] or [CST]-(X)2-C in the treatment of a tumour or in the treatment or prevention of a tumour relapse, and in the manufacture of medicaments therefore.
    Type: Grant
    Filed: February 16, 2009
    Date of Patent: April 7, 2015
    Assignees: Life Sciences Research Partners VZW, Katholieke Universiteit Leuven
    Inventor: Jean-Marie Saint-Remy
  • Marker for determination of sensitivity to triplet combination anti-cancer agent
    Patent number: 8980557
    Abstract: To provide a marker for determining sensitivity of a patient to an anti-cancer agent, which marker can determine whether or not the patient has a therapeutic response to the anti-cancer agent, and novel cancer therapeutic means employing the marker. The marker for determining the sensitivity of a subject to an anti-cancer agent including oxaliplatin or a salt thereof, fluorouracil or a salt thereof, and levofolinate or a salt thereof, the marker containing one or more genes selected from the group consisting of ALAD gene, C20orf43 gene, CABLES1 gene, CDC14B gene, GDA gene, HOXB6 gene, RPL7AP27 gene, TMEM18 gene, and UGT2B10 gene.
    Type: Grant
    Filed: December 2, 2011
    Date of Patent: March 17, 2015
    Assignee: Kabushiki Kaisha Yakult Honsha
    Inventors: Masahiko Nishiyama, Hidetaka Eguchi, Satoru Wada
  • Predictive markers for taxane responsiveness and methods of use thereof
    Patent number: 8980564
    Abstract: Taxanes are widely used in the treatment of breast cancer, although there are currently no validated predictive markers for taxane responsiveness. While the mechanism by which taxanes induce mitotic arrest is well documented, the signaling pathway that links mitotic arrest to cell death, is ill-defined. As described herein, the BH3-only protein Bad and Bik are prognostic indicators for overall survival after adjuvant taxane chemotherapy and a predictive marker for taxane responsiveness.
    Type: Grant
    Filed: November 19, 2010
    Date of Patent: March 17, 2015
    Assignees: The Governors of the University of Alberta, Alberta Health Services
    Inventors: Ing Swie Goping, John R. Mackey, D. Alan Underhill
  • Polypeptide compounds for inhibiting angiogenesis and tumor growth
    Patent number: 8981062
    Abstract: In certain embodiments, this present invention provides polypeptide compositions (e.g., antibodies and antigen binding portions thereof that bind to EphB4), and methods for inhibiting EphB4 activity. In other embodiments, the present invention provides methods and compositions for treating cancer or for treating angiogenesis-associated diseases.
    Type: Grant
    Filed: June 6, 2011
    Date of Patent: March 17, 2015
    Assignee: Vasgene Theapeutics, Inc
    Inventors: Valery Krasnoperov, Nathalie Kertesz, Ramachandra Reddy, Parkash Gill, Sergey Zozulya
  • ErbB interface peptidomimetics and methods of use thereof
    Patent number: 8962793
    Abstract: Peptides, mimetics and antibodies of erbB, TNF, and IgSF receptors and pharmaceutical compositions comprising the same are described. Methods of using such antibodies, peptides, and mimetics in therapeutic, prophylactic, imaging and diagnostic applications are disclosed.
    Type: Grant
    Filed: April 25, 2013
    Date of Patent: February 24, 2015
    Assignee: The Trustees Of The University Of Pennsylvania
    Inventors: Mark I. Greene, Ramachandran Murali, Hongtao Zhang, Mark Richter, Alan Berezov, Qingdu Liu, Jinqiu Chen
  • Treatment prediction involving HMGCR
    Patent number: 8945832
    Abstract: The present invention provides a method for determining whether a mammalian subject having a breast cancer is likely to benefit from an endocrine treatment, comprising the steps of: providing a sample earlier obtained from said subject; evaluating the amount of HMGCR protein or HMGCR mRNA present in at least part of said sample, and determining a sample value corresponding to said amount; comparing the sample value obtained in step b) with a reference value; and, if said sample value is higher than said reference value, concluding that the subject is likely to benefit from an endocrine treatment. Further, a corresponding method of treatment is provided as well as further methods uses and means which may be employed in connection with breast cancer treatment or treatment prediction.
    Type: Grant
    Filed: November 16, 2010
    Date of Patent: February 3, 2015
    Assignee: Atlas Antibodies AB
    Inventors: Mathias Uhlen, Fredrik Ponten, Karin Jirström, Donal J. Brennan
  • Jagged-binding agents and uses thereof
    Patent number: 8945569
    Abstract: Antibodies that specifically bind to an extracellular domain of human Jagged 1 or human Jagged2 and modulate Jagged activity, and methods of using said antibodies to inhibit tumor growth are disclosed. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an anti-Jagged antibody to a patient having a tumor or cancer.
    Type: Grant
    Filed: November 19, 2010
    Date of Patent: February 3, 2015
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Timothy Charles Hoey, Aaron Ken Sato, Alexandra Lazetic, Zhimin Ji
  • Peptide chromatographic purification assisted by combining of solubility parameter and solution conformation energy calculations
    Patent number: 8933196
    Abstract: A method of purifying a compound from a mixture through a chromatographic column loaded with a column adsorbent. The method comprises: applying the mixture to the chromatographic column; eluting the mixture with an elution solvent composition; and collecting the compound; wherein at least one of the column adsorbent and elution solvent is selected based on one of solubility parameters of the compound, column adsorbent, elution solvent, and conformation energy of the compound.
    Type: Grant
    Filed: May 15, 2012
    Date of Patent: January 13, 2015
    Assignees: National Central University, Scinopharm Taiwan Ltd.
    Inventors: Wen-Yih Chen, Li-Chiao Chang, Ruoh-Chyu Ruaan, Ching-Wei Tsai
  • Treatment of cancer involving mutated KRAS or BRAF genes
    Patent number: 8932588
    Abstract: The present invention provides a method of treating cancer in a subject wherein the cancer comprises mutated KRAS or BRAF genes. The method comprises administering to the subject an effective amount of an antibody or antigen binding fragment thereof wherein the antibody or antigen binding fragment thereof competes with SC104 for binding to the human colon cancer cell line Colo205.
    Type: Grant
    Filed: October 29, 2010
    Date of Patent: January 13, 2015
    Assignee: Teva Pharmaceuticals Australia Pty. Ltd.
    Inventors: Norbert A. Kienzle, Anthony G. Doyle, Tony Rowe
  • Biomarkers for head-and-neck cancers and precancers
    Patent number: 8921053
    Abstract: The invention provides markers and methods for detecting head-and-neck precancers, (including OPLs), cancers and related disease conditions in a subject. The invention also provides localization and imaging methods for head-and-neck precancers (including OPLs) and cancers, along with kits for carrying out methods of the invention. The invention further provides therapeutic applications for head-and-neck precancers (including OPLs) and cancers which employ head-and-neck precancer and cancer markers, polynucleotides encoding the markers, and binding agents for the markers.
    Type: Grant
    Filed: February 6, 2009
    Date of Patent: December 30, 2014
    Inventors: K. W. Michael Siu, Ranju Ralhan, Ajay Matta, Leroi V. DeSouza
  • TDF-related compounds and analogs thereof
    Patent number: 8916686
    Abstract: The present invention relates generally to tissue differentiation factor (TDF) analogs. More specifically, the invention relates to structure-based methods and compositions useful in designing, identifying, and producing molecules which act as functional modulators of TDF-like receptors. The invention further relates to methods of detecting, preventing, and treating TDF-associated disorders.
    Type: Grant
    Filed: February 26, 2013
    Date of Patent: December 23, 2014
    Assignee: Thrasos Innovation, Inc.
    Inventors: William D. Carlson, Peter C. Keck, Michael Sworin, Dattatreyamurty Bosukonda
  • Bladder cancer diagnosis composition containing APE1/Ref-1 and bladder cancer diagnostic kit using same
    Patent number: 8916354
    Abstract: Provided are a bladder cancer diagnosis composition containing APE1/Ref-1, a bladder cancer diagnostic kit containing an antibody which specifically binds to the APE1/Ref-1, and a method of measuring APE1/Ref-1 concentration in biological samples through an antigen-antibody binding reaction using the antibody which specifically binds to the APE1/Ref-1. According to the invention, the APE1/Ref-1 protein concentration in serum of bladder cancer patients is significantly higher than in healthy subjects, and more particularly, it significantly increases in the serum of patients with stage 2 or later bladder cancer.
    Type: Grant
    Filed: December 8, 2011
    Date of Patent: December 23, 2014
    Assignee: The Industry & Academy Cooperation in Chungnam National University (IAC)
    Inventors: Byeong-Hwa Jeon, Sung-A Choi, Ju-Hyun Shin
  • Gene and protein expression profiles associated with the therapeutic efficacy of EGFR-TK inhibitors
    Patent number: 8900820
    Abstract: The present invention provides protein and gene expression profiles indicative of whether a patient afflicted with non-small cell lung cancer is likely to be responsive to treatment with a therapeutic compound that is a EGFR-TK inhibitor. By identifying such responsiveness, a treatment provider may determine in advance those patients who would benefit from such treatment, as well as identify alternative therapies for non-responders. The present invention further provide methods of using the gene and protein expression profiles, and assays for identifying the presence of a gene or protein expression profile in a patient sample.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: December 2, 2014
    Assignee: Nuclea Biotechnologies, Inc.
    Inventor: Patrick J. Muraca
  • Methods for the identification, assessment, and treatment of patients with cancer therapy
    Patent number: 8889354
    Abstract: The present invention is directed to the identification of predictive markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain individual and/or combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen. Thus, by examining the expression levels of individual predictive markers and/or predictive markers comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.
    Type: Grant
    Filed: August 31, 2012
    Date of Patent: November 18, 2014
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Barbara M. Bryant, Andrew I. Damokosh, George J. Mulligan
  • Biomarker for colorectal cancer
    Patent number: 8871450
    Abstract: The present invention relates to new methods for predicting the clinical outcome or determining the treatment course in a subject afflicted with solid tumors, like colorectal cancer, and for monitoring the progression of solid tumors, like colorectal cancer, in a subject. Moreover, the present invention relates to a method for stratification of therapy regimen of a subject afflicted with solid tumor entities, such as colorectal cancer, for determining its susceptibility to the treatment with an inhibitor of angiogenesis. Further, the present invention relates to kits allowing performance of the above methods. In particular, the present invention is based on the finding that determining the level or amount of angiopoietin-2 protein in a sample of a subject is useful for conducting the above referenced methods.
    Type: Grant
    Filed: September 6, 2010
    Date of Patent: October 28, 2014
    Assignee: Universität zu Köln
    Inventors: Ulrich Hacker, Valentin Goede, Oliver Coutelle
  • Active protease-resistant antibody FC mutants
    Patent number: 8871204
    Abstract: The present invention relates to modified Fc-containing molecules including modified antibodies characterized by increased resistance to host and pathogen-derived proteases, ability to interact with Fc?R receptors except with Fc?RI, and lack of induction of IL-10 secretion by macrophages, and methods of using and making them.
    Type: Grant
    Filed: July 23, 2012
    Date of Patent: October 28, 2014
    Assignee: Janssen Biotech, Inc.
    Inventors: Randall Brezski, Robert Jordan, William Strohl
  • Extracellular and membrane-associated prostate cancer markers
    Patent number: 8871451
    Abstract: This document relates to methods and materials involved in identifying, assessing, and monitoring prostate cancer in male mammals. For example, this document provides arrays for detecting polypeptides or nucleic acids that can be used to identify prostate cancer in male mammals. In addition, methods and materials for assessing and monitoring prostate cancer in mammals are provided herein.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: October 28, 2014
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: George G. Klee, George Vasmatzis, Farhad Kosari, Eric W. Klee
  • Antibodies that bind to mammalian NGAL and uses thereof
    Patent number: 8846036
    Abstract: The present invention relates to antibodies specific for glycosylated mammalian NGAL, and to methods of making and using such antibodies.
    Type: Grant
    Filed: December 5, 2008
    Date of Patent: September 30, 2014
    Assignee: Abbott Laboratories
    Inventors: Larry G. Birkenmeyer, Suresh M. Desai, David J. Hawksworth, Edward T. Olejniczak, Qiaoqiao Ruan, Robert W. Siegel, Sergey Y. Tetin, Bryan C. Tieman, Bailin Tu, Robert N. Ziemann, Frank C. Grenier, Ryan F. Workman, Lowell Tyner